Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909355 | 1.00 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6909362 | 1.00 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL18577967 | 0.85 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL18577955 | 0.85 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL25869824 | 0.84 | MEN1 (0.46) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL17662480 | 0.84 | MEN1 (0.45) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL2491979 | 0.83 | MEN1 (0.48) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL31252961 | 0.83 | MEN1 (0.47) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11016933 | 0.82 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL10081541 | 0.81 | MEN1 (0.41) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1341745-A1 | RETIFEROL DERIVATIVES AND THEIR USE IN THE TREATMENT OF SKIN DISEASES OR CONDITIONS ASSOCIATED WITH PHOTODAMAGE | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002042247-A1 | RETIFEROL DERIVATIVES AND THEIR USE IN THE TREATMENT OF SKIN DISEASES OR CONDITIONS ASSOCIATED WITH PHOTODAMAGE | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | NR1H2, RFC2, RFC1 | MEN1 4712/4885KMT2A 2693/4885KDM4C 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.